Takeda buys US drug-developer Syrxx
Friday, 11 February, 2005
Japanese pharmaceutical giant Takeda has paid US$270 million in cash to acquire Syrxx, a private drug-development company based in San Diego.
Syrxx is a specialist in high-throughput X-ray crystallography, which it uses to design therapeutics to treat metabolic diseases, cancer, and inflammation. It has several compounds for type 2 diabetes in preclinical and early clinical trials.
Takeda is under pressure to use its cash balance of over 1 trillion yen to fill its poor drug development pipeline. It halted development of a promising diabetes drug late last year.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
